Trial NCT04459247
Publication SHADE - Rastogi A, Postgrad Med J (2020) (published paper)
Funding: No specific funding (None)
Conflict of interest: No
Methods | |
RCT Blinding: Double blinded, no restrictions | |
Location :
Single center / India Follow-up duration (days): 21 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Cholecalciferol 60 000 IU orally once a day for 7 days, afterwards once a week or once a day for another 7 days (if 25 (OH)D level>50 ng/ml). |
|
Control
Placebo | |
Participants | |
Randomized participants : Cholecalciferol =16 Placebo=24 | |
Characteristics of participants N= 40 Mean age : NR 20 males Severity : Mild: n=40 / Moderate: n=0 / Severe: n=0 Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Virus negativity [ Time Frame: 21 days ] | |
In the report Proportions of participants who turn SARS-CoV-2 negative(confirmed twice at 24-hour inter val) before week 3 | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
* |
General comment |
This study is pending contact with authors.
In addition to the published article, the trial registry was used in data extraction and assessment of risk of bias. There were some differences between trial registry and published article in terms of population inclusion criteria. There were no differences in terms of study procedures, treatments and outcomes. Patient selection, study procedures and treatments are poorly described in both the published article and trail registry. There is no information about co-interventions given to participants as part of standard care. The study achieved its target sample size. |